Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Obefazimod

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abivax Ph3 Obefazimod Data Show QoL Gains in Ulcerative Colitis
    Abivax Ph3 Obefazimod Data Show QoL Gains in Ulcerative Colitis

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179780/0/en/Abivax-Announces-Patient-Reported-Outcomes-Data-from-the-Phase-3-ABTECT-Induction-Trials-of-Obefazimod-Demonstrating-Significant-Improvements-in-Quality-of-Life-for-Patients-with-M.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Abivax Presents 8-Week ABTECT Data From Late-Breaking Session
    Abivax Presents 8-Week ABTECT Data From Late-Breaking Session

    06 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/06/3161446/0/en/Abivax-Announces-Late-Breaking-Presentation-of-8-Week-ABTECT-Induction-Trial-Results-in-Participants-With-and-Without-Prior-Inadequate-Response-to-Advanced-Therapies.html

    GLOBENEWSWIRE
    06 Oct 2025
    Share Share
    Abivax Presents 8-Week ABTECT Trial Results With Safety Update
    Abivax Presents 8-Week ABTECT Trial Results With Safety Update

    05 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/05/3161328/0/en/Abivax-Announces-Late-Breaking-Presentation-of-8-Week-ABTECT-Trial-Results-with-Updated-Safety-Data.html

    GLOBENEWSWIRE
    05 Oct 2025
    Share Share
    Abivax To Present Late-Breaking Abtect Phase 3 Data At 2025 UEG
    Abivax To Present Late-Breaking Abtect Phase 3 Data At 2025 UEG

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3158107/0/en/Abivax-Announces-Acceptance-of-Additional-Late-Breaking-Abstract-from-the-ABTECT-Phase-3-Induction-Trials-to-be-Presented-at-2025-United-European-Gastroenterology-UEG-Meeting.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share
    Abivax Presents Obefazimod ABTECT Ph 3 Trials at 2025 UEG Meeting
    Abivax Presents Obefazimod ABTECT Ph 3 Trials at 2025 UEG Meeting

    23 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/23/3155082/0/en/Abivax-Announces-Presentation-of-Late-Breaking-Abstract-for-Obefazimod-from-the-ABTECT-Phase-3-Induction-Trials-at-2025-United-European-Gastroenterology-UEG-Meeting.html

    GLOBENEWSWIRE
    23 Sep 2025
    Share Share
    Abivax Reveals Ph3 Results for Obefazimod in Ulcerative Colitis
    Abivax Reveals Ph3 Results for Obefazimod in Ulcerative Colitis

    22 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/22/3119843/0/en/Abivax-Announces-Positive-Phase-3-Results-from-Both-ABTECT-8-Week-Induction-Trials-Investigating-Obefazimod-its-First-in-Class-Oral-miR-124-Enhancer-in-Moderate-to-Severely-Active-.html

    GLOBENEWSWIRE
    22 Jul 2025
    Share Share